Leal Health, formerly known as Trialjectory, presented data on the negative impact of Eastern Cooperative Oncology Group, or ECOG, performance status scores on cancer patients’ eligibility to enroll in clinical trials at the American Society of Clinical Oncology Genitourinary Cancers Symposium.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
